GREEN 2 of 5 slots filled — scanner found 2 qualifying tickers.
Volume + catalyst = discovery
Regime: GREEN
All signals bullish — full allocation deployed.
The Picks
| Ticker | Scan Price | Gap % | RVOL | Catalyst | ML Hold Prob | ML Expected |
|---|---|---|---|---|---|---|
| SNAP | $6.15 | 9.43 | 1.36 | Analyst: Multiple analyst firms updated price targets for Snap, with BMO raising to $15 (Outperform) while Guggenheim and Citigroup maintained neutral ratings with modest increases to $6.50 and $7 respectively | — | — |
| NVO | $41.17 | 4.70 | 0.72 | Sector: GoodRx's Wegovy HD rollout expansion to self-pay market signals growing demand in the weight-loss drug sector, which could benefit NVO as a major GLP-1 competitor. | — | — |
The Results
| Ticker | Entry | Entry Time | Exit | Exit Time | Method | P/L | % | Catalyst |
|---|---|---|---|---|---|---|---|---|
| SNAP | $6.12 | 9:35 AM | $5.96 | 10:01 AM | VoV Spike | $-258.90 | -2.60 | Analyst: Multiple analyst firms updated price targets for Snap, with BMO raising to $15 (Outperform) while Guggenheim and Citigroup maintained neutral ratings with modest increases to $6.50 and $7 respectively |
| NVO | $41.20 | 9:35 AM | $40.38 | 10:26 AM | VoV Spike | $-198.44 | -1.99 | Sector: GoodRx's Wegovy HD rollout expansion to self-pay market signals growing demand in the weight-loss drug sector, which could benefit NVO as a major GLP-1 competitor. |
Shadow Results
| Ticker | Shadow Entry | Shadow Exit | Exit Time | Method | Shadow P/L | % | Result | Catalyst |
|---|---|---|---|---|---|---|---|---|
| SNAP | $6.12 | $5.96 | 10:01 AM | VoV Spike | $-258.90 | -2.60 | LOSS | Analyst: Multiple analyst firms updated price targets for Snap, with BMO raising to $15 (Outperform) while Guggenheim and Citigroup maintained neutral ratings with modest increases to $6.50 and $7 respectively |
| NVO | $41.20 | $40.38 | 10:26 AM | VoV Spike | $-198.44 | -1.99 | LOSS | Sector: GoodRx's Wegovy HD rollout expansion to self-pay market signals growing demand in the weight-loss drug sector, which could benefit NVO as a major GLP-1 competitor. |
Things to Explore
Interested in our research, validation methodology, and trading system?
Get in TouchWork With Diana
Need a context architect to scaffold your AI agents and facilitate structured learning?
Visit goddev.aiThis post is part of a series documenting MorningEdge's development in real time. The knowledge base contains 0 books, papers, and lab reports totaling 0+ searchable chunks. The trading system described is paper trading only — no real capital is at risk.